[go: up one dir, main page]

CL2019001522A1 - Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. - Google Patents

Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.

Info

Publication number
CL2019001522A1
CL2019001522A1 CL2019001522A CL2019001522A CL2019001522A1 CL 2019001522 A1 CL2019001522 A1 CL 2019001522A1 CL 2019001522 A CL2019001522 A CL 2019001522A CL 2019001522 A CL2019001522 A CL 2019001522A CL 2019001522 A1 CL2019001522 A1 CL 2019001522A1
Authority
CL
Chile
Prior art keywords
treatment
modified oligonucleotides
kidney disease
polycystic kidney
polychistic
Prior art date
Application number
CL2019001522A
Other languages
English (en)
Inventor
Charles R Allerson
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of CL2019001522A1 publication Critical patent/CL2019001522A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONAN EN LA PRESENTE MÉTODOS PARA EL TRATAMIENTO DE UNA ENFERMEDAD POLIQUÍSTICA RENAL, QUE INCLUYE UNA ENFERMEDAD POLIQUÍSTICA RENAL DOMINANTE AUTOSÓMICA, MEDIANTE EL USO DE OLIGONUCLEÓTIDOS MODIFICADOS QUE SE DIRIGEN A MIR-17.
CL2019001522A 2016-12-05 2019-06-04 Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. CL2019001522A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430139P 2016-12-05 2016-12-05

Publications (1)

Publication Number Publication Date
CL2019001522A1 true CL2019001522A1 (es) 2019-10-25

Family

ID=60915610

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001522A CL2019001522A1 (es) 2016-12-05 2019-06-04 Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.

Country Status (18)

Country Link
US (4) US20200165606A1 (es)
EP (1) EP3548503A1 (es)
JP (3) JP7133553B2 (es)
KR (1) KR102759999B1 (es)
CN (1) CN110036019B (es)
AU (1) AU2017370560C1 (es)
CA (1) CA3044896A1 (es)
CL (1) CL2019001522A1 (es)
CO (1) CO2019006234A2 (es)
EA (1) EA201991360A1 (es)
IL (2) IL322679A (es)
MA (1) MA46999A (es)
MX (1) MX2019006332A (es)
MY (1) MY198759A (es)
PH (1) PH12019501224A1 (es)
TW (2) TWI769197B (es)
WO (1) WO2018106566A1 (es)
ZA (1) ZA201903605B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44836A (fr) 2015-08-26 2018-07-04 Univ Texas Procédés de traitement du syndrome polykystique des reins
WO2018155450A1 (ja) 2017-02-21 2018-08-30 国立大学法人大阪大学 アンチセンスオリゴ核酸
CN120519574A (zh) 2018-08-23 2025-08-22 罗氏创新中心哥本哈根有限公司 微小rna-134生物标志物
TW202031268A (zh) * 2018-11-13 2020-09-01 美商雷格勒斯治療公司 用於調節mir-10b 活性之微小rna 化合物及方法
WO2023060237A1 (en) * 2021-10-08 2023-04-13 Regulus Therapeutics Inc. Methods and compositions for treatment of polycystic kidney disease
EP4684014A1 (en) 2023-03-22 2026-01-28 Regulus Therapeutics Inc. Methods for treating nervous system disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2068886T3 (da) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipidholdige præparater
CA2701547C (en) 2007-10-04 2020-03-10 Santaris Pharma A/S Oligonucleotides which target and inhibit micrornas
US8404659B2 (en) * 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
JP2013510576A (ja) * 2009-11-11 2013-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート ｉＰＳ細胞の生成および調節のための方法およびその組成物
EP3105327A4 (en) * 2014-02-12 2017-10-18 Thomas Jefferson University Compositions and methods of using microrna inhibitors
MA44836A (fr) * 2015-08-26 2018-07-04 Univ Texas Procédés de traitement du syndrome polykystique des reins

Also Published As

Publication number Publication date
IL322679A (en) 2025-10-01
IL266871B1 (en) 2025-09-01
MA46999A (fr) 2019-10-09
CN110036019A (zh) 2019-07-19
US20230109466A1 (en) 2023-04-06
US20210095282A1 (en) 2021-04-01
EP3548503A1 (en) 2019-10-09
EA201991360A1 (ru) 2019-11-29
CA3044896A1 (en) 2018-06-14
TW202300647A (zh) 2023-01-01
JP2022169726A (ja) 2022-11-09
KR20190085951A (ko) 2019-07-19
CO2019006234A2 (es) 2019-08-30
IL266871A (en) 2019-07-31
AU2017370560B2 (en) 2021-11-18
ZA201903605B (en) 2023-12-20
WO2018106566A1 (en) 2018-06-14
JP7133553B2 (ja) 2022-09-08
BR112019011164A2 (pt) 2019-10-08
TW201821618A (zh) 2018-06-16
NZ753783A (en) 2025-03-28
JP2024123177A (ja) 2024-09-10
AU2017370560C1 (en) 2022-08-11
KR102759999B1 (ko) 2025-02-03
MY198759A (en) 2023-09-23
TWI769197B (zh) 2022-07-01
US20250283082A1 (en) 2025-09-11
JP2019536804A (ja) 2019-12-19
CN110036019B (zh) 2025-06-06
IL266871B2 (en) 2026-01-01
US20200165606A1 (en) 2020-05-28
AU2017370560A1 (en) 2019-06-06
PH12019501224A1 (en) 2019-09-23
MX2019006332A (es) 2019-08-01

Similar Documents

Publication Publication Date Title
CL2019001522A1 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2018016331A (es) Formas cristalinas de compuesto de triazolopirimidina.
MX2016009862A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
EA201691991A1 (ru) Мультиспецифические антитела
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
MX385749B (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
CR20150205S (es) Almohada de viaje
DK3145934T5 (da) Substituerede-6,8-dioxabicyclo[3.2.1]octan-2,3-diol-forbindelser som ASGPR-targeteringsmidler
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
CL2018003443A1 (es) Tratamientos para el cancer.
SV2019005822A (es) Metodos para tratar el cáncer de próstata
MX2018002354A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
AR110378A1 (es) Métodos para determinar el estado del cáncer colorrectal en una persona
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
CL2019001526A1 (es) Métodos para el tratamiento de la enfermedad renal poliquística.
BR112017002139A2 (pt) ?método para preparar um composto?
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
MX2015012340A (es) Partículas de resinato de fenilefrina.
CO2017000543A2 (es) Lípido que comprende ácido docosapentaenoico
JP2015043197A5 (es)
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima